Anavex Life Sciences Corp (AVXL)

[sokol]

The Biogen July 2018 media onslaught was not the first time it has made glowing assertions about its AD drugs that have so far gone nowhere. See this 2015 article: Biogen Reports Its Alzheimer’s Drug Sharply Slowed Cognitive Decline. https://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html

The above 2015 article says this:

“... the net impression was positive. “Out-of-the-ballpark efficacy, acceptable safety,” Ravi Mehrotra, an analyst at Credit Suisse, wrote on Friday. Shares of Biogen rose $42.33, or 10 percent, to $475.98.” ............

"'A major side effect was a localized swelling in the brain, known as A.R.I.A.-E. This has been seen with other drugs in this class, though the rate for aducanumab seems higher.

Among patients with a genetic variant that raises the risk of getting Alzheimer’s, 55 percent of those who got the highest dose suffered this side effect, and about 35 percent of the high-dose patients dropped out of the trial because of this. Among those without the genetic variant, 17 percent of those who got the highest dose suffered the side effect and 8 percent discontinued treatment.

Biogen said the swelling often did not cause symptoms and probably could be managed by watching for it and reducing doses. Dr. Doody and Dr. Gandy agreed.''

Biogen made enthusiastic statements about Aducanumab in 2015, but here we are in 2018 wherein Biogen makes promising claims about BAN2401.

Interestingly, when Biogen made the March 2015 announcement that its AD drug, Aducanumab, sharply slowed cognitive decline as the above referenced article illustrates, Biogen shares surged $40 plus points, and afterwards the stock price preceded to sink back then as well — similiar to the surge and sink with the 2018 announcement. It seems that history has indeed repeated itself when you look at what occurred in 2015 and 2018.